Colin Bristow
Stock Analyst at UBS
(1.57)
# 3,474
Out of 5,099 analysts
105
Total ratings
38.71%
Success rate
-6.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Neutral | $4 → $10 | $8.01 | +24.84% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $444.64 | +22.80% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $121.34 | -7.70% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $74.10 | +7.96% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.63 | +37.74% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $1.54 | -35.06% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $23.56 | -27.84% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $315.38 | +1.15% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.90 | +110.53% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $25.78 | +8.61% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $97.62 | +22.93% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $177.55 | +13.77% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $2.19 | +630.59% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $726.21 | +51.33% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $22.20 | +652.25% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $993.64 | -57.73% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $11.24 | -82.21% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.17 | +729.49% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $225.18 | -35.16% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $51.21 | +46.46% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.58 | +907.75% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.80 | +55.17% | 1 | Aug 23, 2021 |
enGene Holdings
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $8.01
Upside: +24.84%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $444.64
Upside: +22.80%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $121.34
Upside: -7.70%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $74.10
Upside: +7.96%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.63
Upside: +37.74%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $1.54
Upside: -35.06%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $23.56
Upside: -27.84%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $315.38
Upside: +1.15%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.90
Upside: +110.53%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $25.78
Upside: +8.61%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $97.62
Upside: +22.93%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $177.55
Upside: +13.77%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $2.19
Upside: +630.59%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $726.21
Upside: +51.33%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $22.20
Upside: +652.25%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $993.64
Upside: -57.73%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $11.24
Upside: -82.21%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.17
Upside: +729.49%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $225.18
Upside: -35.16%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $51.21
Upside: +46.46%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.58
Upside: +907.75%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $5.80
Upside: +55.17%